113 related articles for article (PubMed ID: 2690923)
21. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
24. The use of 'CHOP' in the treatment of CLL.
Bennett JM
Br J Haematol; 1990 Apr; 74(4):546. PubMed ID: 2346737
[No Abstract] [Full Text] [Related]
25. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
26. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Fornecker LM; Aurran-Schleinitz T; Michallet AS; Cazin B; Guieze R; Dilhuydy MS; Zini JM; Tomowiak C; Lepretre S; Cymbalista F; Brion A; Feugier P; Delmer A; Leblond V; Ysebaert L
Am J Hematol; 2015 Jun; 90(6):511-4. PubMed ID: 25752923
[TBL] [Abstract][Full Text] [Related]
27. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
28. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
29. When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
Binet JL
Hematol Oncol; 1993; 11 Suppl 1():38. PubMed ID: 8486339
[No Abstract] [Full Text] [Related]
30. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Langerbeins P; Busch R; Anheier N; Dürig J; Bergmann M; Goebeler ME; Hurtz HJ; Stauch MB; Stilgenbauer S; Döhner H; Fink AM; Cramer P; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Am J Hematol; 2014 Dec; 89(12):E239-43. PubMed ID: 25196783
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
32. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
33. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
34. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
35. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
36. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
37. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
38. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
40. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
